The FDA has allowed the use of Temodar for two new purposes in adults with a type of brain tumor called anaplastic astrocytoma. Temodar is a drug that was first approved by the FDA in 1999 to treat adults with a different type of brain tumor called glioblastoma.
Now, the FDA says that adults with newly diagnosed anaplastic astrocytoma can use Temodar along with other treatments, and it can also be used to treat adults with anaplastic astrocytoma that haven't responded well to other treatments.
This change is part of a program called Project Renewal, which focuses on updating information about older cancer drugs. Some common side effects of Temodar include hair loss, tiredness, nausea, vomiting, headaches, constipation, loss of appetite, and seizures.
Shreya Prakash
Clinical Research Coordinator
& Patient Navigator
The EndBrainCancer Initiative
shreya@endbraincancer.org
425-436-8688
16150 NE 85th St., Suite #201
Redmond, WA 98052
endbraincancer.org
